-
Mashup Score: 4ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity - 2 hour(s) ago
ARID1A loss in tumor cells triggers anti-tumor immunity via R-loop-derived cytosolic DNA and activation of the STING-type I interferon pathway, defining a molecular mechanism underlying ARID1A mutant anti-tumor immunity and immunotherapy response observed clinically.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Loss of ARID1A ‘loops’ in STING - 2 hour(s) ago
In a recent article, Maxwell et al. report that loss of tumor cell-specific AT-rich interaction domain 1A (ARID1A), a component of the chromatin remodeling SWI/SNF complex, triggers antitumor immunity via R-loop-mediated upregulation of the type-I interferon (IFN) pathway. These recent findings uncover a molecular mechanism underlying improved responses to immune checkpoint therapy (ICT) seen in patients harboring an ARID1A loss-of-function mutation.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Today's Prayer | The Church of England - 2 hour(s) ago
Join us in today’s prayer.
Source: www.churchofengland.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13Eduardo R Argaiz - Cited by 1,001 - 2 hour(s) ago
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán – Cardiorenal syndrome – Venous Congestion – Renal Physiology
Source: scholar.google.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Evolution: like any other science it is predictable | Philosophical Transactions of the Royal Society B: Biological Sciences - 2 hour(s) ago
Evolutionary biology rejoices in the diversity of life, but this comes at a cost: other than working in the common framework of neo-Darwinian evolution, specialists in, for example, diatoms and mammals have little to say to each other. Accordingly, their …
Source: royalsocietypublishing.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10High5 Oncology TV: ASCO 2024 - 4 hour(s) ago
Für den erfolg reichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreich
Source: high5oncology.tvCategories: General Medicine News, Hem/OncsTweet-
Check out #ASCO24 highlights by @high5md https://t.co/cdE9CFcXfS Faculty @HHammersMD @OncoBellmunt @bjartell @scserendipity1 @nachoduranm @EfstathiouEleni @GoebellJ @grimm_mo @PGrivasMDPhD @y_loriot @amerseburger @CaPsurvivorship @declangmurphy @tompowles1 @brian_rini @montypal https://t.co/VEeVYDEPxZ
-
-
Mashup Score: 3Pulmonary Arterial Hypertension | NEJM - 4 hour(s) ago
Without effective treatment, pulmonary arterial hypertension results in high morbidity and mortality. This review discusses the pathogenesis of the disorder, the thorough clinical evaluation requir…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy. - 6 hour(s) ago
Stereotactic body radiotherapy (SBRT) has firmly established its role in stage I non-small cell lung cancer (NSCLC). Clinical trial results may not fully apply to real-world scenarios. This study aimed to uncover the real-world incidence of acute toxicity and 90-day mortality in SBRT-treated stage I NSCLC patients and develop prediction models for these outcomes.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Mutant ARID1A: igniting cancer immunotherapy - 8 hour(s) ago
Maxwell et al. show that ARID1A loss enhances antitumor immunity by triggering a type I IFN response through the cGAS–STING pathway, thereby promoting T cell infiltration and cytotoxicity. These findings highlight SWI/SNF inhibitors as a strategy to augment immunotherapy efficacy by potentially transforming non-responsive tumors into responders and advancing approaches to cancer treatment.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Hem/OncsTweet
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity https://t.co/zgBN8IAXG0